AMBITION

Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension

Patient / Population Intervention / Exposure Comparison Outcome

In 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.

500

Design

Double-blind RCT

Endpoint

First clinical-failure event

Relevance

ResultHR 0.50 for the primary composite.

Galiè N, et al. N Engl J Med. 2015;373(9):834-844. 10.1056/NEJMoa1413687

Discussion & critique

Established upfront dual combination therapy as the standard initial approach for most patients with PAH.